Daily Roundup

Hydrix Medical Lands Singapore Heart Centre Contract

Hydrix Ltd's subsidiary Hydrix Medical has secured a multi-year contract with Singapore's National Heart Centre, marking another step forward for the company's remote cardiac monitoring platform. The deal, valued at approximately A$0.625 million over three years, will generate around A$0.21 million in annual recurring revenue. The contract involves deploying Hydrix's Implicity cloud-based platform to monitor patients with Cardiac Implantable Electronic Devices, with the technology expected to streamline clinician workflows and enable earlier patient intervention through advanced analytics.

Maronan Metals Delivers Strong Drilling Results

Over in the resources sector, Maronan Metals is making solid progress at its Taroom Trough project. The company's expansive 40,000-meter infill drilling program at the Maronan Underground Project—one of Australia's largest undeveloped silver deposits—continues to intersect impressive silver-lead mineralisation. Recent intercepts include 11.0 metres grading 10.3% lead and 116 grams per tonne silver, results that will feed into a resource update planned for the fourth quarter of FY2027. That update represents a key milestone toward completing a Pre-feasibility Study that should help de-risk and optimize the project's value.

Beach Energy Expands Queensland Footprint

Beach Energy has significantly expanded its presence in Queensland's Taroom Trough through its joint venture with Omega Oil & Gas and Tri-Star E&P Ltd. The partnership has been awarded 1,138 square kilometers of new land, boosting their total operated acreage by 63%—from 1,809 to 2,947 square kilometers. The expansion gives the joint venture access to the basin's highly prospective eastern flank and is expected to enhance their resource potential and development targets as they continue their appraisal program.

Echo IQ Navigates FDA Pathway for EchoSolv HF

Echo IQ Limited is working through FDA concerns regarding its EchoSolv HF application. The company received a Not Substantially Equivalent determination, but the feedback is narrowly focused on statistical analysis supporting clinical validation—the underlying technology itself hasn't drawn any red flags. Echo IQ is exploring multiple routes forward, including an administrative appeal, FDA Ombudsman review, or submitting a new 510(k) application. Management remains confident that clearance remains achievable over the coming quarters.

FOS Capital Raises $1.55 Million

FOS Capital Limited has completed a $1.55 million placement, issuing 12.9 million shares at $0.12 each. Several directors have also committed to subscribe for an additional $310,000 worth of shares, pending shareholder approval at the upcoming Annual General Meeting. The capital will fuel growth initiatives including the Queensland Schools Lighting Upgrade Program and continued expansion of the company's ATS division, while also bolstering the balance sheet to pursue emerging opportunities.